Introduction
The recent findings from the DESTINY-Breast06 Phase III trial signify a potential shift in the treatment landscape for HR-positive, HER2-low metastatic breast cancer. This landmark study evaluates the efficacy of Enhertu (trastuzumab deruxtecan), a specifically engineered antibody drug conjugate, marking significant strides in targeted cancer therapy. These results demonstrate substantial improvements in progression-free survival (PFS) compared to standard chemotherapy, offering new hope for patients with limited treatment options.
Trial Design and Methodology
Overview
DESTINY-Breast06 is a global, randomized, open-label, Phase III trial that compares the effectiveness and safety of Enhertu against the investigator’s choice of standard chemotherapy, which includes options like capecitabine, paclitaxel, or nab-paclitaxel. The study enrolled 866 patients across multiple sites in Asia, Europe, North America, and South America. This diverse cohort included patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) or HER2-ultralow (defined as IHC 0 with membrane staining; IHC >0<1+) advanced or metastatic breast cancer.
Eligibility and Demographics
Participants were eligible if they had no prior chemotherapy for advanced or metastatic disease and showed progression within six months of starting first-line treatment with an endocrine therapy combined with a CDK4/6 inhibitor, or if they had received at least two previous lines of endocrine therapies in the metastatic setting. The trial’s primary endpoint is PFS in the HR-positive, HER2-low patient population, as assessed by blinded independent central review (BICR).
Clinical Outcomes
Progression-Free Survival (PFS)
The results from DESTINY-Breast06 revealed that Enhertu significantly extended PFS in patients with HR-positive, HER2-low metastatic breast cancer compared to standard chemotherapy. This improvement was also observed in the overall trial population, which included patients with HER2-ultralow expression. A prespecified subgroup analysis confirmed that the PFS benefit was consistent across both HER2-low and HER2-ultralow expression groups.
Potential Impact on Overall Survival
Though the overall survival (OS) data were immature at the time of this analysis, there was an observable trend towards OS improvement with Enhertu over chemotherapy in the targeted patient groups. The trial is set to continue to more comprehensively assess OS along with other secondary endpoints.
Safety Profile
The safety profile of Enhertu in this trial aligned with that observed in prior clinical studies, maintaining a consistent track record with no new safety concerns identified. This predictability in safety helps in reinforcing the drug’s suitability for wider clinical use.
Implications for Clinical Practice
Redefining Treatment Paradigms
The findings from DESTINY-Breast06 suggest that Enhertu could set a new standard of care for treating HR-positive, HER2-low and HER2-ultralow metastatic breast cancer. This is particularly significant after one or more lines of endocrine therapy, where few effective options previously existed. “Yes another positive trial! Looking forward to data at ASCO – one big question is impact of sequential therapy. Does sequence matter? Enhertu demonstrated stat significant improvement in PFS in HR+HER2-low MBC after > or = 1 lines of ET in DB06 PhIII trial”, said Hope Rugo, MD commenting on this new data. “AZ reports DESTINYbreast06 trial which is first line study of TDXD vs chemo in her2 low or ultra low (i.e. 0) tumors. So essentially drug works irrespective of Her2 status and “HER2 low” is a thing of the past” also noted Harold J. Burstein, MD, PhD, FASCO.
Broadening the Application of Targeted Therapies
These results encourage a reevaluation of current breast cancer classifications and treatment modalities. The efficacy of Enhertu in a broader range of HER2 expressions might lead to an expansion in the use of targeted therapies beyond traditional classifications.
Conclusion
The DESTINY-Breast06 trial marks a pivotal advancement in the management of metastatic breast cancer, particularly for those with HR-positive, HER2-low subtypes. As the medical community anticipates further data on overall survival and additional analyses, the potential for Enhertu to improve patient outcomes and redefine therapeutic standards remains high. This trial underscores the critical importance of targeted therapy and precision medicine in transforming the prognosis for patients with complex cancers, promising a future where such tailored treatments may become the norm.
Resources:
Link to Press Release: